High performance of a risk calculator that includes renal function in predicting mortality of hypertensive patients in clinical application

Journal of Hypertension

Volumn 32, Issue 6, 2014, Pages 1245-1254

  Ravera, Maura ^a   Cannavò, Rossella ^a   Noberasco, Giuseppe ^b   Guasconi, Alessandro ^c   Cabib, Ursula ^a   Pieracci, Laura ^a   Pegoraro, Valeria ^c   Brignoli, Ovidio ^b   Cricelli, Claudio ^b   Deferrari, Giacomo ^a   Paoletti, Ernesto ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b Italian College of General Practitioners SIMG   (Italy)

^c Cegedim Strategic Data Medical Research ^*  (Italy)

Author keywords

hypertension; mortality; renal function; risk calculators

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ADULT; AGED; ARTICLE; CARDIOVASCULAR MORTALITY; CLINICAL STUDY; CONTROLLED STUDY; DATA BASE; FEMALE; FOLLOW UP; FRAMINGHAM RISK SCORE; GENERAL PRACTITIONER; HUMAN; HYPERTENSION; INTERVENTION STUDY; ITALY; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; UNITED KINGDOM; ALGORITHM; CLINICAL TRIAL (TOPIC); COMPARATIVE STUDY; ELECTROCARDIOGRAPHY; FACTUAL DATABASE; KIDNEY; MIDDLE AGED; MORTALITY; ORGANIZATION AND MANAGEMENT; PATHOPHYSIOLOGY; PRIMARY HEALTH CARE; PROBABILITY; PROCEDURES; RECEIVER OPERATING CHARACTERISTIC; REPRODUCIBILITY; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME;

ADULT; AGED; ALGORITHMS; ANTIHYPERTENSIVE AGENTS; CLINICAL TRIALS AS TOPIC; DATABASES, FACTUAL; ELECTROCARDIOGRAPHY; FEMALE; GREAT BRITAIN; HUMANS; HYPERTENSION; ITALY; KIDNEY; MALE; MIDDLE AGED; PRIMARY HEALTH CARE; PROBABILITY; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; ROC CURVE; TREATMENT OUTCOME;

EID: 84900462776     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0000000000000177     Document Type: Article

References (41)

1. CDC. Vital signs: awareness and treatment of uncontrolled hypertension among adults-United States 2003-2010. MMWR 2012; 61: 703-709.
2. Wolf-Maier K, Cooper RS, Kramer H, Banegas JR, Giampaoli S, Joffres MR, et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension 2004; 43:10-17.
3. Heidenreich PA, Trogdon JG, Khavjou OA, Butler J, Dracup K, Ezekowitz MD, et al., American Heart Association Advocacy Coordinating Committee; Stroke Council; Council on Cardiovascular Radiology and Intervention; Council on Clinical Cardiology; Council on Epidemiology and Prevention; Council on Arteriosclerosis; Thrombosis and Vascular Biology; Council on Cardiopulmonary; Critical Care; Perioperative and Resuscitation; Council on Cardiovascular Nursing; Council on the Kidney in Cardiovascular Disease; Council on Cardiovascular Surgery and Anesthesia, and Interdisciplinary Council on Quality of Care and Outcomes Research. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation 2011; 123:933-944.
4. Kannel WB, Castelli WP, Verter JI, McNamara PM. Relative importance of factors of risk in the pathogenesis of coronary heart disease: The Framingham Study. In: Russek HI, Zohman BL, editors. A Medical-Surgical Symposium Sponsored by the American College of Cardiology and St. Barnabas Hospital, New York City, December 13-15, 1968. Philadelphia: Lippincott; 1971. pp. 97-114.
5. Anderson KM, Wilson PW, Odell PM, Kannel WB.Anupdated coronary risk profile. A statement for health professionals. Circulation 1991; 83:356-362.
6. Anderson KM, Odell PM, Wilson WF, Kannel WB. Cardiovascular disease risk profiles. Am Heart J 1990; 121:293-298.
7. D'Agostino RB Sr, Grundy S, Sullivan LM, Wilson P, CHD Risk Prediction Group. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA 2001; 286:180-187.
8. Fried LP, Borhani NO, Enright P, Furberg CD, Gardin JM, Kronmal RA, et al the Cardiovascular Health Study: design and rationale. Ann Epidemiol 1991; 1:1263-1276.
9. Beswick AD, Brindle P, Fahey T, Ebrahim S. A systematic review of risk scoring methods and clinical decision aids used in the primary prevention of coronary heart disease. London: Royal College of General Practitioners (UK); 2008.
10. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitaliz-ation. N Engl J Med 2004; 351:1296-1305.
11. Hallan S, Astor B, Romundstad S, Aasarød K, Kvenild K, Coresh J. Association of kidney function and albuminuria with cardiovascular mortality in older vs younger individuals: The HUNT II Study. Arch Intern Med 2007; 167:2490-2496.
12. Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, et al., Chronic Kidney Disease Prognosis Consortium. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010; 375:2073-2081.
13. Pocock SJ, McCormack V, Gueyffier F, Boutitie F, Fagard RH, Boissel JP. A score for predicting risk of death from cardiovascular disease in adults with raised blood pressure, based on individual patient data from randomised controlled trials. BMJ 2001; 323:75-81.
14. Sans S, Kesteloot H, Kromhout D the burden of cardiovascular diseases mortality in Europe. Task Force of the European Society of Cardiology on Cardiovascular Mortality and Morbidity Statistics in Europe. Eur Heart J 1997; 18:1231-1248.
15. Deferrari G. General practitioners and nephrologists for outpatient assistance. http://www.controlled-trials.com/isrctn/ISRCTN09810203. [Accessed on 29 March 2013].
16. Blak BT, Thompson M. How does The Health Improvement Network (THIN) data on prevalences on chronic diseases compare with national figures? Value Health 2009; 12:A253.
17. Ravera M, Noberasco G, Weiss U, Re M, Gallina AM, Filippi A, et al. CKD awareness and blood pressure control in the primary care hypertensive population. Am J Kidney Dis 2011; 57:71-77.
18. The Health Improvement Network (THIN). Cegedim Strategic Data (CSD). http://csdmruk.cegedim.com/bibliography/bibliography-01. shtml [Accessed 29 March 2013].
19. Mazzaglia G, Ambrosioni E, Alacqua M, Filippi A, Sessa E, Immordino V, et al. Adherence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patients. Circulation 2009; 120:1598-1605.
20. Filippi A, Paolini I, Innocenti F, Mazzaglia G, Battaggia A, Brignoli O. Blood pressure control and drug therapy in patients with diagnosed hypertension: a survey in Italian general practice. J Hum Hypertens 2009; 23:758-763.
21. National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39 (Suppl 1):S1-S266.
22. Mancia G, de Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al., Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology. 2007 Guidelines for the Management of Arterial Hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25:1105-1187.
23. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 1972; 18:499-502.
24. KDIGO 2012 Clinical Practice Guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 2013; 3:1-150.
25. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) the Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts. Eur Heart J 2012; 33:1635-1701.
26. Schafer JL. Analysis of incomplete multivariate data. London: Chapman & Hall; 1997.
27. Rubin DB. Multiple imputation for nonresponse in surveys. New York: John Wiley & Sons; 1987.
28. Steyerber EW, Van Calster B, Pencina MJ. Performance measures for prediction models and markers: evaluation of predictions and classifications. Rev Esp Cardiol 2011; 64:788-794.
29. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Statist Med 2008; 27:157-172.
30. Pepe MS. Problems with risk reclassification methods for evaluating prediction models. Am J Epidemiol 2011; 173:1327-1335.
31. Drawz PE, Baraniuk S, Davis BR, Brown CD, Colon PJ Sr, Cujyet AB, et al. Cardiovascular risk assessment: addition of CKD and race to the Framingham equation. Am Heart J 2012; 164:925-931.
32. Kavousi M, Elias-Smale S, Rutten JH, Leening MJ, Vliegenthart R, Verwoert GC, et al. Evaluation of newer risk markers for coronary heart disease risk classification: a cohort study. Ann Intern Med 2012; 156:438-444.
33. Weiner DE, Tighiouart H, Griffith JL, Elsayed E, Levey AS, Salem DN, Sarnak MJ. Kidney disease, Framingham risk scores, and cardiac and mortality outcomes. Am J Med 2007; 120:552e1-552e8.
34. Di Angelantonio E, Chowdhury R, Sarwar N, Aspelund T, Danesh J, Gudnason V. Chronic kidney disease and risk of major cardiovascular disease and nonvascular mortality: prospective population based cohort study. BMJ 2010; 341:c4986.
35. Clase CM, Gao P, Tobe SW, McQueen MJ, Grosshennig A, Teo KK, et al., ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial) and TRANSCEND (Telmisartan Randomized Assessment Study in Angiotensin-Converting-Enzyme-Inhibitor Intolerant Subjects with Cardiovascular Disease). Estimated glomerular filtration rate and albuminuria as predictors of outcomes in patients with high cardiovascular risk: a cohort study. Ann Intern Med 2011; 154:310-318.
36. Weiner DE, Tighiouart H, Elsayed EF, Griffith JL, Salem DN, Levey AS, Sarnak MJ the Framingham predictive instrument in chronic kidney disease. J Am Coll Cardiol 2007; 50:217-224.
37. Muller-Nordhorn J, Binting S, Roll S, Willich SN. An update on regional variability in cardiovascular mortality within Europe. Eur Heart J 2008; 29:1316-1326.
38. Ravera M, Noberasco G, Signori A, Re M, Filippi A, Cannavò R, et al. Left-ventricular hypertrophy and renal outcome in hypertensive patients in primary-care. Am J Hypertens 2013; 26:700-707.
39. Olsen MH, Wachtell K, Ibsen H, Lindholm LH, Dahlöf B, Devereux RB, et al., LIFE Study Investigators. Reductions in albuminuria and in electrocardiographic left ventricular hypertrophy independently improve prognosis in hypertension: the LIFE study. J Hypertens 2006; 24:775-781.
40. Eijkelkamp WB, Zhang Z, Brenner BM, Cooper ME, Devereux RB, Dahlöf B, et al. Renal function and risk for cardiovascular events in type 2 diabetic patients with hypertension: the RENAAL and LIFE studies. J Hypertens 2007; 25:871-876.
41. Olsen MH, Wachtell K, Ibsen H, Lindholm L, Kjeldsen SE, Omvik P, et al. Changes in subclinical organ damage versus Framingham risk score for assessing cardiovascular risk reduction during continued antihypertensive treatment. A LIFE Study. J Hypertens 2011; 29:997-1004.